BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 36298832)

  • 1. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
    Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
    Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
    Transpl Int; 2024; 37():12061. PubMed ID: 38328617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
    Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
    Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
    Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
    Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
    Schiaroli E; Gidari A; Brachelente G; Bicchieraro G; Spaccapelo R; Bastianelli S; Pierucci S; Busti C; Pallotto C; Malincarne L; Camilloni B; Falcinelli F; De Socio GV; Villa A; Mencacci A; Francisci D
    J Clin Virol; 2023 Nov; 168():105584. PubMed ID: 37778220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
    Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
    Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
    Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
    Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
    Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N
    Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
    Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
    J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
    Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
    Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
    Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
    Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
    Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
    Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.